Last reviewed · How we verify
NCT06639711
Taurine Eye Drops May Prevent the Progression of Cataract
Phase 1, PHASE2 trial testing Taurine in Cataract in 50 participants. Participants enrolled and being followed up; not accepting new ones.
20 December 2024
Quick facts
| Lead sponsor | University Of Anbar |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 50 |
| Start date | 10 July 2023 |
| Primary completion | 20 December 2024 |
| Estimated completion | 20 December 2024 |
| Sites | 1 location across Iraq |
Drugs / interventions tested
- Taurine — full drug profile →
Conditions studied
- Cataract — all drugs for Cataract →
Sponsor
University Of Anbar
Who can join
18 and older, any sex, with Cataract. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the current intervention study is to determine the effectiveness of taurine containing eye drops (available under brand name VIZILOTON) to prevent the progression of grade I and II senile cataract. This study could answer: * Dose continuous use of taurine-containing eye drops could prevent further deterioration of vision in mild cases of cataract? * The acceptance/ compliance of participants to taurine-containing eye drops. * Could long-term use of taurine-containing eye drops cause adverse effect(s)? Participants will: * Take taurine-containing eye drops (VIZILOTON eye drops) 4 times a day for one year. * Visit eye clinic every 3 months for assessment and visual examination. * Keep notes for their symptoms and their adherence to treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06639711
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Taurine
Trials testing the same drug.
- NCT06128252 — Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer · NA · recruiting
- NCT06123455 — Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer · Phase 2 · unknown
- NCT04772508 — Effect of Amnion Membrane With and Without Taurine on GCF TNF α Level. · NA · completed
- NCT04291352 — Thalassemic Iron Overload Cardiomyopathy is Ameliorated by Taurine Supplementation · NA · unknown
- NCT05149716 — Taurine as a Possible Anti-aging Therapy? · NA · completed
Other recruiting trials for Cataract
Currently open trials in the same condition.
- NCT07301385 — Evaluation of Head-Mounted Spatial Computing and Three-Dimensional (3D) Visualization in Ocular Microsurgery: A Safety a · NA · recruiting
- NCT07462000 — Aqueous Humor and Ocular Tissue Analysis in Glaucoma and Cataract · NA · recruiting
- NCT06891092 — Vivinex Impress XY1-EM vs RayOne EMV · NA · recruiting
- NCT07218796 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting
- NCT07218783 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting
Other University Of Anbar trials
Trials by the same sponsor.
- NCT07138625 — Nebulized 3% Hypertonic Saline Versus Normal Saline in Managing Children With Acute Bronchiolitis: A Randomized Controll · NA · not yet recruiting
- NCT07277959 — Marsupialization of Odontogenic Cysts · completed
- NCT06960278 — Effect of Alum Stone Containing Mucosal Adhesive Patches on Healing of Recurrent Aphthous Stomatitis · EARLY_PHASE1 · completed
- NCT04569825 — Effect of Nasal Steroid in the Treatment of Anosmia Due to COVID-19 Disease · EARLY_PHASE1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06639711 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Of Anbar
- Last refreshed: 9 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06639711.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing